Barclays PLC Has $61.58 Million Stock Position in Labcorp Holdings Inc. $LH

Barclays PLC lowered its stake in Labcorp Holdings Inc. (NYSE:LH) by 28.0% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 214,531 shares of the medical research company’s stock after selling 83,527 shares during the quarter. Barclays PLC owned about 0.26% of Labcorp worth $61,583,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Caldwell Trust Co acquired a new position in shares of Labcorp during the second quarter worth about $25,000. Financial Gravity Companies Inc. acquired a new stake in Labcorp in the 2nd quarter valued at approximately $26,000. Motco acquired a new stake in Labcorp in the 3rd quarter valued at approximately $32,000. Headlands Technologies LLC lifted its stake in Labcorp by 300.0% in the 2nd quarter. Headlands Technologies LLC now owns 128 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 96 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its position in Labcorp by 48.8% during the 3rd quarter. Hantz Financial Services Inc. now owns 122 shares of the medical research company’s stock worth $35,000 after acquiring an additional 40 shares during the last quarter. Institutional investors and hedge funds own 95.94% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on LH shares. Robert W. Baird raised their price target on shares of Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 18th. Morgan Stanley restated an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research report on Friday, January 23rd. Piper Sandler lifted their price target on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research note on Tuesday, February 24th. Finally, JPMorgan Chase & Co. boosted their price target on shares of Labcorp from $319.00 to $330.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 18th. Nine research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $304.82.

Insider Activity

In other news, EVP Der Vaart Sandra D. Van sold 548 shares of the company’s stock in a transaction dated Friday, February 27th. The shares were sold at an average price of $284.91, for a total value of $156,130.68. Following the sale, the executive vice president directly owned 2,579 shares of the company’s stock, valued at approximately $734,782.89. This represents a 17.52% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Brian J. Caveney sold 1,500 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $286.31, for a total value of $429,465.00. Following the transaction, the executive vice president directly owned 30,107 shares in the company, valued at $8,619,935.17. The trade was a 4.75% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 16,113 shares of company stock valued at $4,547,450 in the last 90 days. 0.84% of the stock is owned by company insiders.

Labcorp Trading Up 1.5%

Shares of Labcorp stock opened at $273.77 on Tuesday. The stock has a market cap of $22.56 billion, a P/E ratio of 26.17, a P/E/G ratio of 1.84 and a beta of 1.01. The company has a quick ratio of 1.23, a current ratio of 1.42 and a debt-to-equity ratio of 0.60. Labcorp Holdings Inc. has a 12-month low of $209.38 and a 12-month high of $293.72. The business’s 50 day moving average is $271.42 and its 200-day moving average is $270.18.

Labcorp (NYSE:LH) last released its earnings results on Tuesday, February 17th. The medical research company reported $4.07 earnings per share for the quarter, beating the consensus estimate of $3.95 by $0.12. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. The business had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.56 billion. During the same period last year, the business earned $3.45 earnings per share. The firm’s revenue was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Equities research analysts predict that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, March 12th. Stockholders of record on Friday, February 27th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, February 27th. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. Labcorp’s payout ratio is currently 27.53%.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.